PMC5070038_01
A 65-year-old female with a history of multiple myeloma status postchemotherapy, presenting for a restaging whole-body fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography scan. (a and b) Transverse computed tomography sections of the abdomen showing nodular thickening (arrows) within the posterior gallbladder wall. (c and e) Transverse and coronal fluorine 18-fluorodeoxyglucose positron emission tomography images showing intense focal hypermetabolic activity (arrows) in the region of the gallbladder. (d and f) Fused transverse and coronal positron emission tomography/computed tomography images showing the focal area of hypermetabolic activity corresponding to the nodular thickening within the posterior gallbladder wall (arrows).
JCIS-6-40-g002.jpg
PMC5070038_01_JCIS-6-40-g002.jpg
F1
A 65-year-old female with a history of IgG-kappa chain multiple myeloma status postseveral rounds of chemotherapy with cyclophosphamide, bortezomib, and dexamethasone presented for a restaging F18-FDG PET/CT, as part of posttreatment monitoring [Figure 1].
Postcholecystectomy surveillance whole-body fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography scan. (a and b) Transverse computed tomography sections of the abdomen showing postsurgical changes from cholecystectomy (arrows). (c and e) Transverse and coronal fluorine 18-fluorodeoxyglucose positron emission tomography images showing no metabolic evidence of active malignancy in the gallbladder fossa (arrows). (d and f) Fused transverse and coronal positron emission tomography/computed tomography images confirming that there is no metabolic evidence of active malignancy in the gallbladder fossa (arrows).
JCIS-6-40-g003.jpg
PMC5070038_01_JCIS-6-40-g003.jpg
F2
A restaging F18-FDG-PET/CT 4 months postoperatively revealed no abnormal hypermetabolism within the postsurgical gallbladder fossa [Figure 2].